120
Views
7
CrossRef citations to date
0
Altmetric
Research Article

Development characterizations and evaluation of Poly(-ϵ-caprolactone)-based microspheres for hepatitis B surface antigen delivery

, &
Pages 489-496 | Received 19 Feb 2010, Accepted 24 Apr 2010, Published online: 16 Jun 2010

References

  • Saraf S, Mishra D, Asthana A, Jain R, Singh S, Jain NK. Lipid microparticles for mucosal immunization against hepatitis B. Vaccine 2006;24:45–56.
  • Hilleman MR. Critical overview and outlook: Pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine 2003;21:4626–4631.
  • Agarwal R, Ranjan P. Preventing and treating hepatitis B infection. BMJ 2004;329:1080–1086.
  • Baras B, Benoit MA, Gillard J. Influence of various technological parameters on the preparation of spray-dried poly(-ϵ-caprolactone) microparticles containing a model antigen. J Microencapsul 2000;17:485–498.
  • Perez MH, Zinutti C, Lamprecht A, Ubrich N, Astier A, Hoffman M, Bodmeier R, Maincent P. The preparation and evaluation of poly (-ϵ-caprolactone) microparticles containing both lipophillic and hydrophilic drug. J Cont Rel 2000;65:429–438.
  • Sinha VR, Bansal K, Kumria R, Trehan A. Poly(-ϵ-caprolactone) microspheres and nanospheres: An overview. Int J Pharm 2004;278:1–23.
  • Benoit MA, Baras B, Gillard J. Preparation and characterization of protein loaded poly(-ϵ-caprolactone) microparticles for oral vaccine delivery. Int J Pharm 1999;184:73–84.
  • Jameela SR, Suman N, Jayakrishnan A. Poly(-ϵ-caprolactone) microparticles as a vaccine carrier. J Biomater Sci Polym Ed 1997;8:457–466.
  • Singh J, Pandit S, Bramwell VW, Alpar HO. Diphtheria toxoid loaded poly- (epsilon caprolactone) nanoparticles as mucosal vaccine delivery systems. Method 2006;38:96–105.
  • Tabata Y, Ikada Y. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 1988;9:356–362.
  • Sah H. Stabilization of proteins against methylene chloride/water interface induced denaturation and aggregation. J Cont Rel 1999;58:143–151.
  • Jaganathan KS, Singh P, Prabakaran D, Mishra V, Vyas SP. Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B. J Pharm Pharmacol 2004;56:1243–1250.
  • Lee JH, Park TG, Choi HK. Diphtheria toxoid loaded poly(-ϵ-caprolactone) nanoparticles as mucosal vaccine delivery systems. Int J Pharm 2000;196:75–83.
  • Jaganathan KS, Vyas SP. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 2006;24:4201–4211.
  • Shi L, Caulfield MJ, Chern RT, Wilson RA, Sanyal G, Volkin DB. Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres. J Pharm Sci 2002;91:1019–1035.
  • Thomas C, Gupta V, Ahsan F. Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses. Int J Pharm 2009;379:41–50.
  • Kim BK, Hwang SJ, Park JB, Park HJ. Characteristics of felodipine located poly(-ϵ-caprolactone) microspheres. J Microencap 2005;22:193–203.
  • Youan BBC, Benoit MA, Baras B, Gillard J. Protein-loaded poly (-ϵ-caprolactone) microparticles. I. Optimization of the preparation by (water-in-oil)-in water emulsion solvent evaporation. J Microencap 1999;16:587–599.
  • Florindo HF, Pandit S, Goncalves LM, Alpar HO, Almeida AJS. Streptococcus equi antigen adsorbed onto surface modified poly-caprolactone microspheres induce humoral and cellular specific immune responses. Vaccine 2008;26:4168–4177.
  • Singh M, Li XM, McGee JP, Zamb T, Koff W, Wang CY. Controlled release microparticles as a single dose hepatitis B vaccine: Evaluation of immunogenicity in mice. Vaccine 1997;15:475–481.
  • Borges O, Silva M, De Sousa A, Borchard G, Hans EJ, Cordeiro-da-Silva A. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen. Int Immunopharmacol 2008;8:1773–1780.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.